CN1285843A - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
CN1285843A
CN1285843A CN98812979A CN98812979A CN1285843A CN 1285843 A CN1285843 A CN 1285843A CN 98812979 A CN98812979 A CN 98812979A CN 98812979 A CN98812979 A CN 98812979A CN 1285843 A CN1285843 A CN 1285843A
Authority
CN
China
Prior art keywords
compound
fluoro
adenosine
alkyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98812979A
Other languages
English (en)
Chinese (zh)
Inventor
R·P·C·库辛斯
B·科克斯
C·D·埃德雷
A·M·K·彭尼尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1285843A publication Critical patent/CN1285843A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN98812979A 1997-11-08 1998-11-06 化合物 Pending CN1285843A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9723589.9 1997-11-08
GBGB9723589.9A GB9723589D0 (en) 1997-11-08 1997-11-08 Chemical compounds

Publications (1)

Publication Number Publication Date
CN1285843A true CN1285843A (zh) 2001-02-28

Family

ID=10821760

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98812979A Pending CN1285843A (zh) 1997-11-08 1998-11-06 化合物

Country Status (29)

Country Link
US (1) US6455510B1 (https=)
EP (2) EP1030857B1 (https=)
JP (1) JP2001522857A (https=)
KR (1) KR20010031875A (https=)
CN (1) CN1285843A (https=)
AP (1) AP2000001801A0 (https=)
AR (1) AR011229A1 (https=)
AT (1) ATE273990T1 (https=)
AU (1) AU2048399A (https=)
BR (1) BR9813976A (https=)
CA (1) CA2309200A1 (https=)
CO (1) CO5021135A1 (https=)
DE (1) DE69825780T2 (https=)
EA (1) EA200000392A1 (https=)
EE (1) EE200000285A (https=)
ES (1) ES2222621T3 (https=)
GB (1) GB9723589D0 (https=)
HR (1) HRP20000275A2 (https=)
HU (1) HUP0004082A2 (https=)
IL (1) IL135964A0 (https=)
IS (1) IS5477A (https=)
MA (1) MA26565A1 (https=)
NO (1) NO20002361L (https=)
PE (1) PE20000013A1 (https=)
PL (1) PL340921A1 (https=)
SK (1) SK6722000A3 (https=)
TR (1) TR200002131T2 (https=)
WO (1) WO1999024449A2 (https=)
ZA (1) ZA9810125B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
GB0106867D0 (en) 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
EP1434782A2 (en) 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US7265111B2 (en) 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
JP4596913B2 (ja) * 2002-08-15 2010-12-15 ギリアード・パロ・アルト・インコーポレイテッド Ａ１アデノシン受容体の部分および完全アゴニスト
KR20050097971A (ko) 2003-02-03 2005-10-10 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ₁아데노신 수용체의 부분 및 전 작용제
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
JP2008512457A (ja) * 2004-09-09 2008-04-24 アメリカ合衆国 Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
JP2011509305A (ja) * 2008-01-09 2011-03-24 ピージーエックスヘルス、リミテッド、ライアビリティー、カンパニー Ａ２ａｒアゴニストによる神経障害性疼痛の髄腔内治療
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
ES2831416T3 (es) 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
JP2026500305A (ja) 2022-12-16 2026-01-06 アストラゼネカ・アクチエボラーグ ２，６，９三置換プリン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575959A (en) * 1969-05-13 1971-04-20 Merck & Co Inc 5'-substituted ribofuranosyl nucleosides
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
TR200002131T2 (tr) 2001-01-22
HRP20000275A2 (en) 2000-12-31
EP1030857A2 (en) 2000-08-30
NO20002361D0 (no) 2000-05-05
SK6722000A3 (en) 2001-01-18
ES2222621T3 (es) 2005-02-01
HUP0004082A2 (hu) 2001-04-28
DE69825780T2 (de) 2005-01-13
IS5477A (is) 2000-05-03
EE200000285A (et) 2001-08-15
US6455510B1 (en) 2002-09-24
AP2000001801A0 (en) 2000-06-30
PE20000013A1 (es) 2000-01-21
ZA9810125B (en) 2000-05-05
CO5021135A1 (es) 2001-03-27
EP1457495A1 (en) 2004-09-15
NO20002361L (no) 2000-07-05
WO1999024449A3 (en) 1999-08-19
IL135964A0 (en) 2001-05-20
AU2048399A (en) 1999-05-31
ATE273990T1 (de) 2004-09-15
EP1030857B1 (en) 2004-08-18
PL340921A1 (en) 2001-03-12
BR9813976A (pt) 2000-09-26
AR011229A1 (es) 2000-08-02
DE69825780D1 (de) 2004-09-23
WO1999024449A2 (en) 1999-05-20
CA2309200A1 (en) 1999-05-20
JP2001522857A (ja) 2001-11-20
KR20010031875A (ko) 2001-04-16
GB9723589D0 (en) 1998-01-07
MA26565A1 (fr) 2004-12-20
EA200000392A1 (ru) 2000-12-25

Similar Documents

Publication Publication Date Title
CN1285843A (zh) 化合物
CN1300165C (zh) 3－β－呋喃核糖基噻唑并[4,5－d]嘧啶核苷及其应用
CN1045088C (zh) 用作pnp抑制剂的嘌呤和鸟嘌呤化合物
CN1151167C (zh) 嘌呤衍生物
CN1291994C (zh) 核苷酸膦酸酯类似物前药及其筛选和制备方法
CN1285842A (zh) 化合物
CN1271070C (zh) 用作腺苷A2α受体的配体的三唑基－咪唑并吡啶和三唑基嘌呤类的衍生物及其作为药物的应用
CN101056879A (zh) 作为a3和a1腺苷受体激动剂的嘌呤衍生物
CN1084177A (zh) 具抗病毒和抗癌活性的2′-脱氧-2′，2′-二氟(4-取代嘧啶)核苷以及中间体
CA2685748A1 (en) Azido purine nucleosides for treatment of viral infections
CN1285844A (zh) 化合物
JP2005533777A (ja) Ｒｎａ抗ウイルス剤としての炭素環ヌクレオシドアナログ
CN1228770A (zh) 具有抗高血压,保护心脏,抗缺血和抗脂解性质的化合物
CA2904692A1 (en) Modified 4'-nucleosides as antiviral agents
AU2014354775A1 (en) Nucleotides for the treatment of liver cancer
CN1119869A (zh) N-烷基-2-取代的atp类似物
JP2018532726A (ja) ４’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
CN1446217A (zh) 用作磷酸二酯酶抑制剂的β－咔啉衍生物
WO1991019713A1 (fr) Derive de nucleoside de pyrimidine
CN1135485A (zh) 2，9-二取代的嘌呤-6-酮类化合物
CN1103401A (zh) 制备吡咯并嘧啶及其中间体的方法
CN1047866A (zh) N-杂芳基-嘌呤-6-胺的制备方法及其药用
CN1036579A (zh) 新型炔属、氰基和丙二烯系芒霉素/腺苷衍生物
CN1278809A (zh) 取代的苯并二氢吡喃衍生物
CN1033632A (zh) 新颖的隐陡头霉素/腺苷衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication